5 articles suggested by Vivek Subbiah
Vivek Subbiah shared a few must-reads paper on X:
1. Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Authors: Catharina J P Op ‘t Hoog, Niven Mehra, Marc Maliepaard, Kalijn Bol, Prof Hans Gelderblom, Prof Gabe S Sonke, Adrianus J de Langen, Niels W C J van de Donk, Jeroen J W M Janssen, Prof Monique C Minnema, Prof Nielka P van Erp, Emmy Boerrigter,
Authors: Georgina V. Long, Evan J. Lipson, F. StephenHodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf
Authors: Qianwei Liu, Fen Yang, Krisztina D. László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang,
Authors: Danyi Wang, Brian Elenbaas, Karthikeyan Murugesan, Kunal Shah, Meagan Montesion, Ioannis Gounaris, Juergen Scheuenpflug, Giuseppe Locatelli And Zheng Feng
a
A
Source: Vivek Subbiah/X
Read more posts by Vivek Subbiah on oncodaily.com
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.
He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023